NNI-351
id:
nni-351-180-13965271
title:
NNI-351
text:
NNI-351 is an orally active inhibitor of DYRK1ATooltip dual specificity tyrosine-phosphorylation-regulated kinase 1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/NNI-351
date created:
2017-06-04T11:12:18Z
date modified:
2024-09-05T14:05:26Z
main entity:
{"identifier":"Q30315125","url":"https://www.wikidata.org/entity/Q30315125"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/3/3c/NNI-351.svg","width":980,"height":405}
fields total:
13
integrity:
16